Two people start tirzepatide the same week. Same dose, same slow titration up the ladder. One of them texts a friend on day four to say the constant background thinking-about-food has gone quiet. The other, a month in, is hungry again an hour after dinner and starting to wonder whether the medication is doing anything at all.
Same drug and same dose but two very different results. For a long time the answer to “why?” was a shrug and a vague line about everyone being different.
This article is general information, not medical advice. Traqr does not diagnose any condition and does not assign anyone an obesity subtype. Nothing here is a reason to start, stop or change a medication, and nothing here is a claim about what will happen to you. Decisions about your treatment, and any question about which subtype applies to you, are for you and your prescriber.
This year researchers put some actual biology behind that shrug.
What the Mayo researchers found
In 2026, a team led by gastroenterologist Andres Acosta at Mayo Clinic published a study in Gastroenterology looking at 483 adults with obesity. Instead of treating obesity as one condition, they sorted people by how their bodies actually handle appetite, and landed on three biological subtypes.
One of those subtypes got the nickname: “hungry gut” and roughly one in four respondents fell into this group. Their bodies make lower levels of the gut’s own appetite-regulating hormones, and their stomachs empty faster, so they feel hungry again sooner after a normal-sized meal and tend to snack more through the day rather than eat huge portions.
Over six months on tirzepatide, the hungry-gut group lost about 21.5% of their body weight. Everyone else in the study averaged 11.7%. Same medication, nearly double the result, sorted by biology the participants couldn’t feel and didn’t choose.
The subtype was identified with a lab-and-questionnaire workup — a research test, run by clinicians, measuring hormones and stomach emptying. It is not a thing you can diagnose from how hungry you felt yesterday, and it is not something a tracking app can read off your logs. The 21.5% is an average across a group of people and it describes a pattern researchers saw, not a promise to any individual on any given week.
Why appetite responds differently at all
Strip out the nickname and the study is really about one useful idea: appetite is not a single dial.
At least three systems are running at once. Your gut releases its own hormones, including natural GLP-1, that tell your brain you’ve had enough. Your stomach empties at its own speed, which changes how long “full” lasts. And your brain’s reward system rates how much you want food in the first place, which is the part people feel as food noise.
GLP-1 medications lean on all three so the size of the change you feel depends on which of those systems was running loudest for you before you started. If your hunger was driven mostly by something the drug happens to act on strongly, the shift can be dramatic. If it was driven by something the drug touches less, the same dose feels gentler. Neither is you doing it right or wrong. It’s just where your own appetite was set when the medication arrived.
That reframes a frustration a lot of people carry. Watching someone else describe their food noise vanishing while yours only dropped a little isn’t evidence you’re failing at this. It’s the same point the Mayo study makes with hormones and a stopwatch: people start in different places.
The part you can actually see
The Mayo workup happens in a clinic. What you have at home is your own experience of appetite, day to day, and it’s worth capturing in your app, because it’s your expression of the exact same thing.
Traqr lets you log three separate things on a simple 0–100 scale, whenever you want: how hungry you feel, how full a meal leaves you, and how loud your food noise is. Kept up for a couple of weeks, those turn into three trend lines that are yours and no one else’s. You can see whether your hunger is easing or just felt that way on a good day, whether fullness is lasting longer than it used to, whether the food noise has dropped from a 70 to a 20 or only seems quieter than last month.
None of that is a diagnosis, and Traqr will never put a subtype label on it. It’s your self-reported data, plain and simple. But it answers the practical question most people carry, the one about whether their own appetite is changing and by how much. Which biological category you fall into is a doctor’s question. Whether your hunger is settling, week to week, is one you can watch yourself.
Your appetite has a shape across the dose cycle
There’s one more thing the trend lines pick up that a single “how hungry am I today” can’t.
For a lot of people on a weekly medication, appetite isn’t flat across the week. It can run quieter in the days right after a dose and creep back up towards the end of the cycle. Traqr’s Cycle view lines your logged hunger, fullness and food noise up against where you are between doses, so you can see whether that pattern is real for you or not.
That’s useful for a practical reason. If you know your food noise reliably gets louder on days six and seven, a hungry evening late in the cycle reads as a known rhythm rather than a sign the medication has stopped working. And on a plateau, when the scale goes quiet for a few weeks and stops rewarding you, an appetite trend that’s still holding steady is often the honest signal that something is still working underneath.
The Mayo study is the clinic’s-eye view: hormones, stomach emptying, a number that sorts hundreds of people. Your hunger, fullness and food-noise logs are the close-up, personal end of the same thing — the part you can see change on your own screen, without anyone assigning you a label to explain it.
Sources
- Mayo Clinic / Gastroenterology — Acosta A et al., “A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response” (2026). Study of 483 adults with obesity identifying biological obesity subtypes; the “hungry gut” subgroup (~1 in 4) showed reduced natural GLP-1 synthesis and faster gastric emptying, and lost ~21.5% of body weight on tirzepatide over six months versus ~11.7% in other participants. Subtype identified via clinical lab-and-questionnaire workup.
- Mayo Clinic News Network — “Study identifies patients with obesity most likely to benefit from GLP-1-based treatment” (2026): plain-language summary of the three-subtype finding and the hungry-gut result, with senior author Andres Acosta.
- Background on appetite regulation — the gut’s endogenous GLP-1 and other satiety hormones, gastric emptying rate, and central reward signalling as distinct contributors to appetite, all of which GLP-1 receptor agonists act on. General physiology, not specific to any individual’s response.
